Your email has been successfully added to our mailing list.

×
0 0 0 0 0 -0.0128205128205129 0.00345167652859962 -0.00690335305719924
Stock impact report

XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis

XBiotech Inc. (XBIT) 
Last xbiotech inc. earnings: 8/9 03:01 pm Check Earnings Report
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
Company Research Source: GlobeNewswire
AUSTIN, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced the first patient was enrolled in a clinical study evaluating bermekimab therapy in adults with systemic sclerosis (SSc), otherwise known as scleroderma, a devastating inflammatory syndrome characterized by chronic inflammation in the blood vessels, skin, and other organs. The randomized double-blind, placebo-controlled trial will evaluate efficacy of weekly bermekimab monotherapy versus placebo. The primary endpoint of the study will be measured at 12 weeks, and will assess SSc disease severity using a combination of rheumatological, clinical, and physiological measures. The study will randomize patients 1:1 to receive either weekly subcutaneous injections of bermekimab or placebo. The study will also include an open label weekly bermekimab treatment regimen during weeks 13-24, where patients will continue to be evaluated using the same endpoints. SSc is characterized by systemic inflammation that r Show less Read more
Impact Snapshot
Event Time:
XBIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for XBIT alerts
Opt-in for
XBIT alerts

from News Quantified
Opt-in for
XBIT alerts

from News Quantified